PROJECTS & PUBLICATIONS
Simmpyra-1 and -2 are two patent-pending novel drug candidates designed to treat triple-negative breast cancer. SIMMPHARM (Simmpyra Pharmaceuticals) developed these compounds in collaboration with the Milwaukee Institute for Drug Discovery. These drugs efficiently kill TNBC cells without causing any toxicity in normal mammary epithelial cells and regress human TNBC tumors in a PDX humanized mouse model. Both Simmpyra-1 & -2 are 1000-times more potent inhibitors of STAT3 compared to known STAT3 inhibitors.
Simmpyra-3 is patent-pending selective AMP kinase agonist that increases muscle strength, promotes cognitive skill, and increases learning and memory.
PUBLICATIONS: Coming soon...........